Blog Where innovation, insight & ideas combine. Contact Us Ask The Experts Home Blog Translational Pharmaceutics, Dr. Helen Baker, Dr. Vanessa Zann, Drug Development Consulting, Drug Product, Philadelphia, Miami Accelerating Drug Development with Translational Pharmaceutics® Read Now Categories View all categories14C Radiolabeling505(b)(2)AlnwickBioanalysisBiopharmaceuticsBlogCandidate DevelopmentCandidate SelectionCareersClinical PharmacologyClinical Trial ManufacturingClinical Trial SuppliesColleague StoriesCommercial ManufacturingCorporate UpdatesCRDMOData SciencesDenise SuttonDennis HendersonDr. Adam Robinson-MillerDr. Andrew LewisDr. Aruna RailkarDr. Asma PatelDr. Gareth JenkinsDr. Helen BakerDr. Peter ScholesDr. Richard Castledine Dr. Stuart MairDr. Stuart McDougallDr. Vanessa ZannDrug Development ConsultingDrug ProductDrug Product OptimizationDrug Substance to Drug ProductEarly DevelopmentFirst-in-HumanFormulation DevelopmentFreeThink ASAPprimeGamma ScintigraphyGLP-1 TherapeuticsHealthy Volunteer TrialsHelen BakerHigh Potency APIsHuman ADMEIain ShawIan NisbetICP-MSIndustry CollaborationInhalationJohn EntwistleJohn McDermottKevser SevimLate DevelopmentMartin Wing-KingMiamiMicrobiologyModeling and SimulationModified ReleaseNazim KanjiNichole CaparelliNottinghamOmer AlpOncologyOrphan DrugsOrphan RarePaige BellisPediatricsPeptidesPharmacy CompoundingPhase 1 TrialsPhiladelphiaPR&DProject ManagementQuality AssuranceRare DiseasesReadingRegulatoryScientific AchievementsScientific InnovationScintigraphySite SpotlightSolid-State CharacterizationSolubility EnhancementThierry Van NieuwenhoveDrug SubstanceIntegrated ProgramsSustainabilityTranslational Pharmaceutics Publish Date View all time20252024202320222021202020192018 Fulltext search 81 - 85 of 122 results Drug Substance, Translational PharmaceuticsSmall Molecule Drug Substance Development - Part 2: How do you streamline manufacturing of your drug substance?Drug Substance, Translational PharmaceuticsSmall Molecule Drug Substance Development - Part 2: How do you streamline manufacturing of your drug substance?Learn more Drug Substance, Translational PharmaceuticsSmall Molecule Drug Substance Development – Part 1: How do you design a safe and scalable synthetic route for your drug substance?Drug Substance, Translational PharmaceuticsSmall Molecule Drug Substance Development – Part 1: How do you design a safe and scalable synthetic route for your drug substance?Learn more Translational Pharmaceutics, First-in-Human, John McDermottIntegrated Development Strategies - Part 1: Leveraging clinical data to accelerate from first-in-human (FIH) to proof of concept (POC)Translational Pharmaceutics, First-in-Human, John McDermottIntegrated Development Strategies - Part 1: Leveraging clinical data to accelerate from first-in-human (FIH) to proof of concept (POC)Learn more Scientific Achievements, Dr. Peter ScholesReflecting on our Scientific Achievements in 2021Scientific Achievements, Dr. Peter ScholesReflecting on our Scientific Achievements in 2021Learn more Modified Release, Formulation DevelopmentStrategies for accelerating the development of modified release oral formsModified Release, Formulation DevelopmentStrategies for accelerating the development of modified release oral formsLearn more Pagination First page « First Previous page ‹ Previous … Page 15 Page 16 Page 17 Page 18 Page 19 … Next page Next › Last page Last » Learn more about Quotient Sciences At a Glance We are a drug development and manufacturing accelerator for the global pharmaceutical industry. Learn More Our Locations Access directions and information about our facilities in the US & UK. Browse Locations Careers See what life is like at Quotient Sciences and how you can join our global team. Browse Jobs Get in touch Humanity can't afford to wait, so neither can we. Let's talk
